Precision molecular diagnostics company DiaCarta has received an emergency use authorization (EUA) from the US Food and Drug Administration for its QuantiVirus MPXV test, a real-time multiplex PCR test intended for the qualitative detection of monkeypox virus DNA in human lesion swab specimens.
The test from the Pleasanton, CA-based company is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?